OptimizeRx Sales Pipeline Up 79% to $84 Million in 2019; Company Reiterates Strong Q4 and 2020 Outlook
“Our sales pipeline growth is being driven by an accelerated migration to digital solutions by pharma, along with a greater focus on patient experience,” noted
“In addition to the significant pipeline growth,” continued Silvestro, “we recently reported that we had five enterprise opportunities totaling
“Our integrated platform approach also allows us to address the needs of a much larger group of manufacturers and we have identified 29 whose needs directly align with our new platform solution,” added Silvestro. “The benefits of this integration have begun to appear in the growth of our aggregate pipeline, including an increase of our average deal size from
According to
About
The cloud-based solution supports patient adherence to medications and better healthcare outcomes with real-time access to financial assistance, prior authorization, education and critical clinical information.
For more information, follow the company on Twitter, LinkedIn or visit www.OptimizeRx.com.
Important Cautions Regarding Forward Looking Statements
This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended, and such as in section 21E of the Securities Act of 1934, as amended. These forward-looking statements should not be used to make an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
OptimizeRx Contact
Tel (248) 651-6568 x807
dbaker@optimizerx.com
Media Relations Contact
Tel (860) 800-2344
nicolebrooks@innsena.com
Investor Relations Contact
Tel (949) 432-7557
oprx@cma.team
Source: OptimizeRx Corporation